New triple-drug treatment stops pancreatic cancer in its tracks, a mouse study finds

Illustration of a tumor, shown in red, growing on a pancreas, depicted in blue.

A triple-drug therapy for pancreatic cancer has shown promise in early animal tests, pointing to a potential new treatment for a disease with a notoriously low survival rate.

Considered one of the deadliest common cancers, pancreatic cancer has a five-year relative survival rate around 13% — meaning roughly 87% of people with the cancer are expected to die within five years of diagnosis. That survival rate can plummet as low as 1% for people diagnosed in very late stages of the disease.